SEC Form 4	1
------------	---

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287	
Estimated average burg	len 0.5	
hours per response:	0.5	

obligations may continue. See Instruction 1(b).			Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per respo	nse: 0.5						
			or Section 30(h) of the Investment Company Act of 1940								
1. Name and Address of Reporting Person <sup>*</sup> Lyon Joseph Douglas			2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [ CORT ]	5. Relationship of (Check all applical Director		(s) to Issuer 10% Owner					
(Last) C/O CORCEPT	Last) (First) (Middle) C/O CORCEPT THERAPEUTICS		3. Date of Earliest Transaction (Month/Day/Year) 04/01/2024	X Officer (g below)	ive title See Remarks	Other (specify below)					
INCORPORATED 149 COMMONWEALTH DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applic Line) X Form filed by One Reporting Person							
(Street) MENLO PARK	CA	94025		Form file Person	d by More than O	ne Reporting					
	CA	94023	Rule 10b5-1(c) Transaction Indication								
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
	Ta	able I - Non-Dei	rivative Securities Acquired, Disposed of, or Benefi	cially Owned							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	04/01/2024		М		500	Α	\$11.35	7,814(1)	D	
Common Stock	04/01/2024		<b>S</b> <sup>(2)</sup>		500	D	\$26.007	7,314(1)	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Exp		Expiration Da	Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy)	<b>\$</b> 11.35	04/01/2024		М			500	(3)	02/08/2029	Common Stock	500	\$0.00	42,667	D	

## Explanation of Responses:

1. Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements

2. The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.

3. Fully exercisable

## Remarks:

Chief Accounting & Technology Officer

/s/ Joseph Douglas Lyon

\*\* Signature of Reporting Person

04/03/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.